Artal Group S.A. Travere Therapeutics, Inc. Transaction History
Artal Group S.A.
- $214 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding TVTX
# of Institutions
203Shares Held
85.1MCall Options Held
776KPut Options Held
912K-
Armistice Capital, LLC New York, NY7.65MShares$161 Million1.78% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$161 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.9MShares$146 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.68MShares$98.8 Million2.23% of portfolio
-
Woodline Partners LP San Francisco, CA4.34MShares$91.6 Million0.55% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.35B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...